RAPT Therapeutics, Inc.

NasdaqGM:RAPT Stok Raporu

Piyasa değeri: US$77.8m

RAPT Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

RAPT Therapeutics' CEO is Brian Wong, appointed in Aug 2015, has a tenure of 9.25 years. total yearly compensation is $6.59M, comprised of 9.2% salary and 90.8% bonuses, including company stock and options. directly owns 1.41% of the company’s shares, worth $1.10M. The average tenure of the management team and the board of directors is 4.8 years and 7.5 years respectively.

Anahtar bilgiler

Brian Wong

İcra Kurulu Başkanı

US$6.6m

Toplam tazminat

CEO maaş yüzdesi9.2%
CEO görev süresi9.3yrs
CEO sahipliği1.4%
Yönetim ortalama görev süresi4.8yrs
Yönetim Kurulu ortalama görev süresi7.5yrs

Son yönetim güncellemeleri

Recent updates

RAPT: CCR4 Inhibition Presses On For Now With Oncology Focus

Jul 24

Companies Like RAPT Therapeutics (NASDAQ:RAPT) Could Be Quite Risky

Jun 13
Companies Like RAPT Therapeutics (NASDAQ:RAPT) Could Be Quite Risky

RAPT Therapeutics: Dip Following FDA Clinical Hold Creates Asymmetric Opportunity

May 20

Is RAPT Therapeutics (NASDAQ:RAPT) In A Good Position To Invest In Growth?

Feb 21
Is RAPT Therapeutics (NASDAQ:RAPT) In A Good Position To Invest In Growth?

We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth

Sep 12
We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth

We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth

May 10
We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth

We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely

Feb 07
We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely

We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely

Oct 12
We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely

RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

Jan 25
RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

Oct 15
RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

RAPT Therapeutics (RAPT) skyrockets 100% on positive RPT193 data in early-stage atopic dermatitis study

Jun 14

RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

Jun 08
RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

Should You Take Comfort From Insider Transactions At RAPT Therapeutics, Inc. (NASDAQ:RAPT)?

Mar 15
Should You Take Comfort From Insider Transactions At RAPT Therapeutics, Inc. (NASDAQ:RAPT)?

We Think RAPT Therapeutics (NASDAQ:RAPT) Can Easily Afford To Drive Business Growth

Feb 15
We Think RAPT Therapeutics (NASDAQ:RAPT) Can Easily Afford To Drive Business Growth

RAPT Therapeutics' (NASDAQ:RAPT) Stock Price Has Reduced 56% In The Past Year

Jan 18
RAPT Therapeutics' (NASDAQ:RAPT) Stock Price Has Reduced 56% In The Past Year

RAPT Therapeutics: Interesting Asset, But Doubtful History And Bad Market Reaction

Jan 08

Here's What RAPT Therapeutics, Inc.'s (NASDAQ:RAPT) Shareholder Ownership Structure Looks Like

Dec 21
Here's What RAPT Therapeutics, Inc.'s (NASDAQ:RAPT) Shareholder Ownership Structure Looks Like

The Independent Chairman of the Board of RAPT Therapeutics, Inc. (NASDAQ:RAPT), William Rieflin, Just Bought 12% More Shares

Nov 23
The Independent Chairman of the Board of RAPT Therapeutics, Inc. (NASDAQ:RAPT), William Rieflin, Just Bought 12% More Shares

Earnings Beat: RAPT Therapeutics, Inc. (NASDAQ:RAPT) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Nov 19
Earnings Beat: RAPT Therapeutics, Inc. (NASDAQ:RAPT) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

RAPT Therapeutics tumbles 25% despite promising FLX475 data in multiple cancers

Nov 16

CEO Tazminat Analizi

Brian Wong'un ücretlendirmesi RAPT Therapeutics'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2024n/an/a

-US$120m

Mar 31 2024n/an/a

-US$118m

Dec 31 2023US$7mUS$605k

-US$117m

Sep 30 2023n/an/a

-US$109m

Jun 30 2023n/an/a

-US$99m

Mar 31 2023n/an/a

-US$93m

Dec 31 2022US$5mUS$580k

-US$84m

Sep 30 2022n/an/a

-US$79m

Jun 30 2022n/an/a

-US$76m

Mar 31 2022n/an/a

-US$73m

Dec 31 2021US$3mUS$540k

-US$69m

Sep 30 2021n/an/a

-US$64m

Jun 30 2021n/an/a

-US$60m

Mar 31 2021n/an/a

-US$56m

Dec 31 2020US$4mUS$500k

-US$53m

Sep 30 2020n/an/a

-US$53m

Jun 30 2020n/an/a

-US$49m

Mar 31 2020n/an/a

-US$47m

Dec 31 2019US$2mUS$447k

-US$43m

Sep 30 2019n/an/a

-US$39m

Jun 30 2019n/an/a

-US$40m

Mar 31 2019n/an/a

-US$37m

Dec 31 2018US$1mUS$425k

-US$36m

Tazminat ve Piyasa: Brian's total compensation ($USD6.59M) is above average for companies of similar size in the US market ($USD655.65K).

Tazminat ve Kazançlar: Brian's compensation has increased whilst the company is unprofitable.


CEO

Brian Wong (52 yo)

9.3yrs

Görev süresi

US$6,591,617

Tazminat

Dr. Brian Russell Wong, M.D., Ph.D. serves as Venture Partner at The Column Group, LLC since joining the firm in 2022. He has been Chief Executive Officer and Director at RAPT Therapeutics, Inc. since Augu...


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Brian Wong
CEO, President & Director9.3yrsUS$6.59m1.41%
$ 1.1m
Rodney K. Young
CFO, Principal Accounting Officer & Secretary4.9yrsUS$2.18m0.034%
$ 26.2k
William Ho
Chief Medical Officer9.5yrsUS$1.90m0.045%
$ 35.1k
Steve Young
Vice President of Technologyno dataVeri yokVeri yok
Dirk Brockstedt
Chief Scientific Officer5.4yrsUS$1.48m0.074%
$ 57.6k
Michael Listgarten
General Counsel1.8yrsVeri yokVeri yok
Gwen Carscadden
Chief Human Resources Officer2.5yrsVeri yokVeri yok
Paul Kassner
Senior Vice President of Quantitative & Computational Biology4.7yrsVeri yokVeri yok
David Wustrow
Senior Vice President of Drug Discovery & Preclinical Development5.8yrsVeri yokVeri yok
Jennifer Nicholson
Senior Vice President of Regulatory Affairs & Quality Assurance2.2yrsVeri yokVeri yok
Nipun Davar
Senior Vice President of Technical Operationsless than a yearVeri yokVeri yok

4.8yrs

Ortalama Görev Süresi

57.5yo

Ortalama Yaş

Deneyimli Yönetim: RAPT's management team is considered experienced (4.8 years average tenure).


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Brian Wong
CEO, President & Director9.3yrsUS$6.59m1.41%
$ 1.1m
William Rieflin
Independent Chairman of the Board9.5yrsUS$300.28k0.27%
$ 211.2k
Mary Gray
Independent Director4.9yrsUS$277.78k0%
$ 0
Andrew Pardoll
Member of Scientific Advisory Board7.5yrsVeri yokVeri yok
Philip Greenberg
Member of Scientific Advisory Board7.5yrsVeri yokVeri yok
Alexander Rudensky
Chairman of Scientific Advisory Boardno dataVeri yokVeri yok
Antoni Ribas
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Scott Antonia
Member of Scientific Advisory Board7.2yrsVeri yokVeri yok
Emma Guttman-Yassky
Member of Scientific Advisory Board5.3yrsVeri yokVeri yok
Michael Giordano
Independent Director6.8yrsUS$267.78k0%
$ 0
Linda Kozick
Independent Director7.9yrsUS$260.78k0%
$ 0
Robert Zamboni
Member of Scientific Advisory Boardno dataVeri yokVeri yok

7.5yrs

Ortalama Görev Süresi

65yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: RAPT's board of directors are considered experienced (7.5 years average tenure).